tiprankstipranks
Advertisement
Advertisement

HK:1177 Stock Latest News

Sino Biopharm Wins NMPA Review Nod for First Domestic CD3/EpCAM Bispecific Antibody
Company AnnouncementsSino Biopharm Wins NMPA Review Nod for First Domestic CD3/EpCAM Bispecific Antibody
3d ago
Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial
PremiumCompany Announcements
Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial
4d ago
Sino Biopharmaceutical Wins China Nod for First-Line Use of Novel Breast Cancer Drug
PremiumCompany Announcements
Sino Biopharmaceutical Wins China Nod for First-Line Use of Novel Breast Cancer Drug
4d ago
Sino Biopharmaceutical Plans Board Changes Ahead of 2026 AGM
PremiumCompany Announcements
Sino Biopharmaceutical Plans Board Changes Ahead of 2026 AGM
11d ago
Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate
PremiumCompany Announcements
Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate
11d ago
Sino Biopharmaceutical Bolsters Leadership for Global Clinical Development
PremiumCompany AnnouncementsSino Biopharmaceutical Bolsters Leadership for Global Clinical Development
12d ago
Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026
Premium
Company Announcements
Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026
19d ago
Sino Biopharm Wins China Approval for New Alveolar Soft Part Sarcoma Therapy
Premium
Company Announcements
Sino Biopharm Wins China Approval for New Alveolar Soft Part Sarcoma Therapy
20d ago
Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck
PremiumCompany Announcements
Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck
21d ago
Sino Biopharm Advances CLDN18.2 ADC With First Patient Dosed in Global Phase III Gastric Cancer Trial
PremiumCompany Announcements
Sino Biopharm Advances CLDN18.2 ADC With First Patient Dosed in Global Phase III Gastric Cancer Trial
25d ago
Sino Biopharm Advances Kylo-11 With First U.S. Patient in Phase II Trial
PremiumCompany Announcements
Sino Biopharm Advances Kylo-11 With First U.S. Patient in Phase II Trial
1M ago
Sino Biopharm Wins Early Greater Bay Area Nod for Naldemedine in Opioid-Induced Constipation
PremiumCompany Announcements
Sino Biopharm Wins Early Greater Bay Area Nod for Naldemedine in Opioid-Induced Constipation
1M ago
Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205
PremiumCompany AnnouncementsSino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205
1M ago
Sino Biopharmaceutical Completes Hygieia Acquisition With Performance-Linked Payout Structure
Premium
Company Announcements
Sino Biopharmaceutical Completes Hygieia Acquisition With Performance-Linked Payout Structure
1M ago
Sino Biopharm Buys HK$27 Million in Shares for Award Scheme
Premium
Company Announcements
Sino Biopharm Buys HK$27 Million in Shares for Award Scheme
1M ago
Sino Biopharm lifts profit on surging innovative drug sales in 2025
PremiumCompany Announcements
Sino Biopharm lifts profit on surging innovative drug sales in 2025
2M ago
Sino Biopharm Proposes HKD 0.05 Final Dividend for 2025
PremiumCompany Announcements
Sino Biopharm Proposes HKD 0.05 Final Dividend for 2025
2M ago
Sino Biopharmaceutical to Rebrand English Stock Short Name and Website
PremiumCompany Announcements
Sino Biopharmaceutical to Rebrand English Stock Short Name and Website
2M ago
Sino Biopharmaceutical Wins MSCI ESG Rating Upgrade to AA on Green and Social Push
PremiumCompany Announcements
Sino Biopharmaceutical Wins MSCI ESG Rating Upgrade to AA on Green and Social Push
2M ago
Sino Biopharm Wins NMPA Nod for First-in-Class Osteoarthritis Drug Trial
PremiumCompany AnnouncementsSino Biopharm Wins NMPA Nod for First-in-Class Osteoarthritis Drug Trial
2M ago
Sino Biopharmaceutical Sets Board Meeting to Approve 2025 Results and Consider Dividend
Premium
Company Announcements
Sino Biopharmaceutical Sets Board Meeting to Approve 2025 Results and Consider Dividend
2M ago
Sino Biopharm Reports Breakthrough Phase III Success for IDH1 Inhibitor in Biliary Tract Cancer
Premium
Company Announcements
Sino Biopharm Reports Breakthrough Phase III Success for IDH1 Inhibitor in Biliary Tract Cancer
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >